MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.

By Huan Yang, W. Kong, Lili He, Jian-jun Zhao, Joshua D. O'Donnell, Jia-Wang Wang, R. Wenham, D. Coppola, P. Kruk, S. Nicosia and 1 more. Cancer Research, 2008

1,161 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/f6ff842f55716509c50bf1d65662e1ce69fd49b5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Zhuhong You
2. Di Xie
3. Qi Zhao
4. Xing Chen
5. Ç. Gerçel-Taylor
6. Jiuyong Li
7. Murray J. Cairns
8. Bing Liu

In Molecular Biology

1. Zhuhong You
2. Di Xie
3. Qi Zhao
4. Matthew D. Hall
5. Lynn M. Pouliot
6. D. Shen
7. Xing Chen
8. Ç. Gerçel-Taylor

Citations in the corpus

• The mammalian ovary from genesis to revelation. (2009, background): “Overexpressionofmir-214 inhuman ovarian cancer cell lines reduced PTEN expression and conferred resistance to cisplatin-induced apoptosis by activating the AKT pathway, whereas knockdown of mir214 sensitized cells to cisplatin (647).”
• Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin (2008, background): “1A and B ; Supplementary Table S1) in MCF-7/DOX cells was associated with the decreased level of their targets ERa, RB1, and PTEN proteins (32–36), respectively, resulting in estrogen insensitivity and increased survival of MCF-7/ DOX resistant cells.”
• Identifying miRNAs, targets and functions (2012, background): “ported differentially regulated miRNAs in diverse cancer types, such as breast cancer [5], lung cancer [6], prostate cancer [7], colon cancer [8], ovarian cancer [9] and head and neck cancer [10].”
• MicroRNAs and complex diseases: from experimental results to computational models (2019, positive): “Especially, accumulated studies have shown that miRNAs can function as oncogenes or tumor suppressors in the initiation, progression and metastasis of various types of cancers [98], including breast cancer [95], prostate cancer [99], lung cancer [100], colon cancer [101], ovarian cancer [102].”
• Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors (2009, neutral): “In addition, transcriptional or translational repression of PTEN expression in the absence of PTEN mutation is also a common characteristic of multiple tumour types (Wiencke et al, 2007; Yang et al, 2008).”
• Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes (2012, background): “Yang et al. (2008a) reported miRNA expression profiling in human ovarian cancer and found that miR-214 induces cell survival and cisplatin resistance by targeting PTEN.”
• MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA (2008, methodology): “Immunoblotting analysis was carried out as described previously ( 52 ).”
• MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. (2008, background): “As specific microRNAs associated with tumor tissues are identified that predict prognosis, including therapeutic resistance (such as let-7i, miR-16, miR-21 and miR-214) [31,32], their presence in tumor exosomes can also be assessed to further define the utility of exosomal microRNA profiling as a pr”